Tiziana Life Sciences Ltd (TLSA NASDAQ) stock market data APIs
$1.0482
0.04(3.8%)
as of October 16, 2026
Try our APIs with
free plan!
Tiziana Life Sciences Ltd Financial Data Overview
Price chart is built with
Anychart
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Prev. Close
1.0482
Open
1.0901
High
1.0957
Low
1.0217
52 wk Range
0.76-2.1
Market Cap
134 M
Shares Outstanding
127 M
Revenue
-3 595 000
EPS
-0.05
Beta
0.44
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tiziana Life Sciences Ltd data using free add-ons & libraries
Get Tiziana Life Sciences Ltd Fundamental Data
Tiziana Life Sciences Ltd Fundamental data includes:
- Net Revenue: -3 595 000
- EBITDA: -21 120 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Tiziana Life Sciences Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2025-10-03
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tiziana Life Sciences Ltd News
New
Wall Street ends on a mixed note as Dow gains despite semiconductor slump
4:20pm: Tariff concerns linger Wall Street finished Monday on a mixed note, with renewed weakness in technology and semiconductor stocks pulling the Nasdaq and S&P 500 lower while the Dow Jones Indus...
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, ant...
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Key Points Dauntless Investment Group bought 116,863 shares of Innoviva in an estimated trade of $2.52 million last quarter. The quarter-end position value rose by $2.74 million, reflecting both trad...
Tiziana Releases Positive Update For Intranasal Foralumab In Treating Multiple Sclerosis
(RTTNews) - Tiziana Life Sciences (TLSA), a biotechnology company, on Tuesday released positive clinical data from the ongoing expanded access program for intranasal Foralumab in treating non-active s...
Get Tiziana Life Sciences Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.